Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
Background: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeutic option. The aim of our study was to evaluate outcomes and p...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/11/2170 |
| _version_ | 1797458655430311936 |
|---|---|
| author | Ingrid Garajová Fabio Gelsomino Massimiliano Salati Anna Mingozzi Marianna Peroni Stefania De Lorenzo Alessandro Granito Francesco Tovoli Francesco Leonardi |
| author_facet | Ingrid Garajová Fabio Gelsomino Massimiliano Salati Anna Mingozzi Marianna Peroni Stefania De Lorenzo Alessandro Granito Francesco Tovoli Francesco Leonardi |
| author_sort | Ingrid Garajová |
| collection | DOAJ |
| description | Background: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeutic option. The aim of our study was to evaluate outcomes and prognostic parameters in patients with intrahepatic cholangiocarcinomas treated with second-line chemotherapy. Methods: A total of 255 consecutive metastatic intrahepatic cholangiocarcinoma (ICC) patients were retrospectively reviewed and clinicopathologic and survival data were collected. Results: Fourty-four percent of ICC patients underwent second-line chemotherapy. In particular, younger ICC patients with better ECOG PS status, and with disease control after first-line chemotherapy were those who were treated with second-line treatments. Median progression-free survival in the patients treated with second-line chemotherapy was 3 months. Finally, the patients affected by intrahepatic cholangiocarcinoma with better ECOG PS, with prior surgical resection of the primary tumor, who responded to first-line chemotherapy, and had better progression-free survival with second-line chemotherapy, were associated with better outcomes in multivariate analysis. Conclusions: Not all patients seem to benefit from second-line chemotherapy. To improve therapeutic decisions, performance status and disease control with first-line chemotherapy should lead to the decision on the usefulness of second-line treatments in advanced ICC patients. |
| first_indexed | 2024-03-09T16:40:15Z |
| format | Article |
| id | doaj.art-9cbd149114394cddba536f6d8eecaa65 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T16:40:15Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-9cbd149114394cddba536f6d8eecaa652023-11-24T14:52:27ZengMDPI AGLife2075-17292023-11-011311217010.3390/life13112170Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?Ingrid Garajová0Fabio Gelsomino1Massimiliano Salati2Anna Mingozzi3Marianna Peroni4Stefania De Lorenzo5Alessandro Granito6Francesco Tovoli7Francesco Leonardi8Medical Oncology Unit, University Hospital of Parma, 43126 Parma, ItalyDepartment of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyDepartment of Oncology and Hematology, University Hospital of Modena, 41124 Modena, ItalyMedical Oncology Unit, University Hospital of Parma, 43126 Parma, ItalyMedical Oncology Unit, University Hospital of Parma, 43126 Parma, ItalyOncology Unit, Azienda USL Bologna, 40127 Bologna, ItalyDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 41138 Bologna, ItalyDivision of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 41138 Bologna, ItalyMedical Oncology Unit, University Hospital of Parma, 43126 Parma, ItalyBackground: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeutic option. The aim of our study was to evaluate outcomes and prognostic parameters in patients with intrahepatic cholangiocarcinomas treated with second-line chemotherapy. Methods: A total of 255 consecutive metastatic intrahepatic cholangiocarcinoma (ICC) patients were retrospectively reviewed and clinicopathologic and survival data were collected. Results: Fourty-four percent of ICC patients underwent second-line chemotherapy. In particular, younger ICC patients with better ECOG PS status, and with disease control after first-line chemotherapy were those who were treated with second-line treatments. Median progression-free survival in the patients treated with second-line chemotherapy was 3 months. Finally, the patients affected by intrahepatic cholangiocarcinoma with better ECOG PS, with prior surgical resection of the primary tumor, who responded to first-line chemotherapy, and had better progression-free survival with second-line chemotherapy, were associated with better outcomes in multivariate analysis. Conclusions: Not all patients seem to benefit from second-line chemotherapy. To improve therapeutic decisions, performance status and disease control with first-line chemotherapy should lead to the decision on the usefulness of second-line treatments in advanced ICC patients.https://www.mdpi.com/2075-1729/13/11/2170intrahepatic cholangiocarcinomasecond-line chemotherapyprognosis |
| spellingShingle | Ingrid Garajová Fabio Gelsomino Massimiliano Salati Anna Mingozzi Marianna Peroni Stefania De Lorenzo Alessandro Granito Francesco Tovoli Francesco Leonardi Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? Life intrahepatic cholangiocarcinoma second-line chemotherapy prognosis |
| title | Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? |
| title_full | Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? |
| title_fullStr | Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? |
| title_full_unstemmed | Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? |
| title_short | Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? |
| title_sort | second line chemotherapy for intrahepatic cholangiocarcinomas what is the real gain |
| topic | intrahepatic cholangiocarcinoma second-line chemotherapy prognosis |
| url | https://www.mdpi.com/2075-1729/13/11/2170 |
| work_keys_str_mv | AT ingridgarajova secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain AT fabiogelsomino secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain AT massimilianosalati secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain AT annamingozzi secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain AT mariannaperoni secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain AT stefaniadelorenzo secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain AT alessandrogranito secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain AT francescotovoli secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain AT francescoleonardi secondlinechemotherapyforintrahepaticcholangiocarcinomaswhatistherealgain |